Onconetix (ONCO) Revenue (2024 - 2026)
Onconetix (ONCO) posted quarterly Revenue of $88225.0 for Q4 2025, down 87.61% year-over-year from $711976.0 in Q4 2024, and down 70.95% quarter-over-quarter from $303651.0 in Q3 2025.
Onconetix (ONCO) Revenue (2024 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Revenue for 2 consecutive years, with $88225.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Revenue fell 87.61% year-over-year to $88225.0; the TTM figure through Mar 2026 stood at $498370.0 (down 74.0% YoY), while the FY2025 annual figure was $600000.0, down 76.23% from the prior year.
- Revenue slipped to $88225.0 in Q4 2025 per ONCO's latest filing, from $303651.0 in the prior quarter.
- Across five years, Revenue topped out at $711976.0 in Q4 2024 and bottomed at $88225.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 674.14 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 17,120.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17,120.00 |
| Mar 31, 2026 | 21,457.00 |
| Dec 31, 2025 | 88,225.00 |
| Sep 30, 2025 | 303,651.00 |
| Jun 30, 2025 | 106,494.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 711,976.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 704,848.00 |
| Mar 31, 2024 | 700,433.00 |